c-tau protein levels in people with early-onset psychosis are higher than healthy people

A study published in the International Early Psychosis Association (IEPA) in Milan, Italy, showed that c-tau protein levels in people with early-onset psychosis (onset earlier than 18 years) are significantly higher than those of healthy people. The conclusion was reached through a series of research using recombinant rat proteins.

Early onset psychosis (EOP), including early onset of schizophrenia (EOS) and emotional non-schizophrenia mental disorders, is a severe mental illness with the onset time before the age of 18, and the cause of EOP is not currently clear. Previous studies have shown that these patients often have severe neurological loss, such as inattention, lack of executive capacity and memory loss. The researchers believe that these symptoms show neurocognitive loss of the patients.

In diseases related to the loss of neurocognitive ability, such as Alzheimer's disease, deterioration is often associated with increased levels of neurodegenerative biomarkers such as tau proteins in blood and cerebrospinal fluid. In this study, the researchers analyzed plasma tau levels (including tau total protein [t-tau] and ruptured tau protein [c-tau] in EOP patients, these marks are related to dementia and trauma brain injury.)

The researchers analyzed plasma t-tau and c-tau levels in 20 patients and the control group (n = 20). The results showed a significant increase in c-tau levels in patients with an average of 2150 pg / ml in EOP compared to an average of 1100 pg / ml in the control group.

"This study shows that tau protein metabolism may affect EOP," the researchers conclude, "This study provides new insights into the pathogenesis of EOP as well as new therapeutic strategies." Flarebio offers good recombinant proteins such as recombinant CDH12 at competitive prices.

New CRISPR tool has been released by Chinese scientists

Recently, the international academic journal Nature Methods published the latest research results of the Targeted AID-mediated mutagenesis (TAM) enablesefficient genomic diversification in mammalian cells by the Changxing Research Group of the Shanghai Institutes for Biological Sciences / Shanghai Jiaotong University School of Medicine and Institute of Health Sciences. They combined activation-induced cytidine deaminase (AID) with CRISPR-dCas9 and used recombinant mouse proteins to create an effective genetic diversity tool for high-throughput screening of functional variants. This is a new method of DNA Base editing which is efficient and high-throughput.

Inspired by the "mutant self" mechanism and under the guidance of researcher Chang Xing, Dr. Ma Yunqing and Zhang Jiayuan discovered that when the nucleosidase-deficient Cas9 protein and the cytosine deaminase AID that induced antibody high-frequency mutation were fused, cytosine and guanine can be random to the other three bases on sgRNA-targeted genomic DNA. This new method can be specific to the cell DNA sequence diversity, the completion of genetic screening so as to analyze single nucleotide mutations function. At the same time, under the assist of a peptide inhibitor, dCas9-AID can induce specific cytosine to thymidine conversion to achieve precise editing of single base. The researchers used dCas9-AIDx to target BCR-ABL in chronic myelogenous leukemia cells, which effectively identified known mutations and new mutations that confer resistance to imatinib. Studies have shown that dCas9-AID is a very useful genetics tool and can screen functional acquired variation at the single-base level.

The team further demonstrated that this approach could rapidly and effectively mimics the heterogeneity of drug resistance in tumor cells, predict possible mutations in drug resistance, thus improving small molecule inhibitors and studying interaction of small molecules and protein targets. The results of the study provide a new approach of analysis of gene regulatory elements at the level of molecular evolution, gene therapy and single base level. Flarebio offers recombinant proteins of good quality such as recombinant CDH12 at good prices.

A certain protein may be the starting factor for Alzheimer's disease

Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis all are likely to be related to structural collapse of the accumulation of proteins and brain inflammatory response. However, although there are many studies on recombinant rat proteins, the specific causes and mechanisms are unclear.

Researchers at the University of Louisville School of Medicine have found that proteins produced by intestinal bacteria can cause structural protein folding errors in the brain and inflammation of the brain. Their study found that intestinal bacteria can produce a protein has structure similar to the brain protein, and this protein will lead to an increase in the number of α-synuclein in the brain. In the brains of patients with Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, structural abnormalities of alpha-synuclein and associated amyloid accumulation can be found.

α-Synuclein is a protein existing in the brain of normal humans. In the brain of patients with Alzheimer's disease and Parkinson's disease, the protein will accumulate and form amyloid substances, thereby impairing brain function. Experts suspected that intestinal bacteria can produce a protein which can bring structural folding abnormalities of proteins in brain, and those brain proteins with abnormal structure will deposite in the brain. In addition, experts also suspected that the protein secreted by intestinal bacteria will promote the inflammatory response of brain.

A study implanted E. coli which can produce this protein in the intestine of experimental mice, while the other group of control mice was implanted with E. coli that could not produce the protein. The results showed that the experimental group mice brain produced more α-synuclein, and the brain inflammation was also stronger than the control group. There was a similar study on nematode also showed a similar result.

The expert said, "These two similar studies on different animals suggest that certain protein secreted by enteric bacilli may be the starting factor for Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Understanding this is very important, because many of these factors are not genetically determined. While coliform bacteria are part of our body, and we have many possible ways to influence the number of these bacteria, thereby treating the disease.

Colorectal bacteria play an important role in age-related brain degenerative diseases. Finally, experts said, "We are continuing our efforts to explore this mechanism, thus exploring further possible therapies." Flarebio offers good-quality recombinant proteins like recombinant CDH12 at competitive prices.

New antibody therapy of Alzheimer’s disease may come true someday

In study on degenerative nervous disease shows that an antibody therapy can reduce the light β- amyloid plaques in the brain of Alzheimer's patients. The study has been published in the British journal Nature this week. The study provides preclinical data and preliminary results of clinical trials in stageⅠ. Through research of recombinant proteins like recombinant dog proteins, it is found that both of them support to further develop the antibody for the treatment of Alzheimer's disease.

The gradual accumulation of β- amyloid proteins in the brain is a sign of of Alzheimer's disease. It is generally considered that β- amyloid-related toxicity triggers synaptic dysfunction and neurodegeneration, both of which can lead to Alzheimer's disease. However, clinical therapy targeted to β- amyloid proteins has always been unsuccessful currently.

This time, researcher Alfred Sang Duoke and colleagues from the famous American biotech company Biogen reported the development condition of human monoclonal antibody Aducanumab. The drug was developed by Biogen for treatment of Alzheimer's disease. It can be selectively directed to fight against β- amyloid proteins and is known as the "new hope to overcome Alzheimer's disease". Now, researchers say that in the genetically-modified mouse model, Aducanumab can enter the brain and dose dependently reduces soluble and insoluble β- amyloid proteins.

The authors also conducted a double-blind and randomized, placebo-controlled Phase Ⅰ clinical trial to evaluate the safety and tolerability showed by Alzheimer's patients after monthly injecting Aducanumab to patients with mild cognitive impairment or mild dementia and brain exist β- amyloid deposits. In one-year period, 165 patients were monthly injected placebo or Aducanumab. After 54 weeks of treatment, β- amyloid proteins in the brain of patients injected with Aducanumab significantly reduced. The higher the dose, the greater the decrease amplitude of plaque; while the brain of patients inhected with placebo showed no significant changes. During the research, 40 patients discontinued treatment, because 20 of them showed adverse reactions, including dose-dependent amyloid-related imaging abnormalities.

The authors conculded that demonstration that anti-β- amyloid therapy can delay cognitive decline will completely change the way of understanding, treatment and prevention of Alzheimer's disease. Flarebio provides you with high-quality recombinant proteins such as recombinant CDH12 at good prices.

It is likely to find a way to prevent disease recurrence

In a study published in the journal New England Journal of Medicine, researchers from US and Dutch found mutations of genes related to immune system in metastatic melanoma patients. These patients initially responded to the treatment against PD-1, but the disease relapsed after six months.

Research team from University of California at Los Angeles (UCLA), Jonsson Comprehensive Cancer Center and Netherlands Cancer Institute conducted exon sequencing for the tumor samples of four patients with metastatic melanoma before they received pembrolizumab drug therapy. The researchers also analyzed the protein coding sequence of tumor samples through recombinant mouse proteins after late recurrence. By comparing sequencing results of tumor samples before treatment and after relapse, they found the mutations associated with checkpoint blocking resistance.

The researchers found suspected mutations in three patients. In the body of one of them, they found truncation mutations which affected β-2-microglobulin (B2M) encoding gene. This mutation causes the expression of type I major histocompatibility complex (MHC) molecules, and the molecules can be recognized by CD8T cells immune system. Another two recurrent tumors showed function mutations of gene functions of JAK1 or JAK2 genes, and these two gene encodings interfere related kinases.

First author of the study, doctoral Jesse Zaretsky from Antoni Ribas Laboratory at the University of California at Los Angeles said, "These mutations make the tumor produce resistance to the way of immune system killing tumors. For example, JAK mutations are associated with interferon receptors and make tumors become insensitive to the signals of slowing down tumor growth and killing tumors."

The team established cell lines of recurrent tumor patients with JAK2 function-loss mutations. Making used of nCounter expression system of NanoString Technologies company, they found that JAK2 protein expression deletion after treatment, decrease of interferon-γ activity and protein yield reduction are all associated with antigen presentation and T cell activity. The researchers plan to focus on the study of JAK2 protein using recombinant dog proteins, as JAK2 protein becomes the new key of treating cancer.

Zaretsky said that more large-scale studies are needed to observe whether this kind of mutations identified in patients with recrudescent metastatic melanoma is common in patients receiving other disease checkpoint blocking therapy and to look for other potential resistance-associated mutations. Researchers are now creating cell line models to study the pathogenesis of these resistance mutations, hoping to find a way to prevent disease recurrence. Flarebio provides you with good-quality recombinant proteins including recombinant CDH12 at good prices.

It may gain opposite effects by fighting free radicals to delay aging

As we all know, free radicals can cause damage, death and aging of cell, but scientists' recent discovery just refutes this theory. Recently, researchers from University of Michigan have discovered a new protein. This protein can strongly fight against free radicals in the body, but the free radicals are a radical activator of this protein at the same time. The mutations of this kind of genes in the human body would induce rare neurodegenerative disease. The research of recombinant proteins just indicates the conclusion.

Head of the search and associate professor of cellular and molecular biology Xu Haoxing at University of Michigan said, "As material recycling center of the cell, lysosome can remove the necrotic cell fragments. When lysosome senses excessive free radicals in the cell, it will open the calcium channels of film surface and then start the expression of many genes and enhanced lysosomal scavenging capacity. The ultimate goal is to remove the damaged part of the cell.

Professor Xu said, "The role of free radicals in cells is very special. If there is a chemical substance that can directly start the open of ion channels. Then the effects of oxidative stress in aging diseases can be reduced, and the level of free radicals and cell damage will also decrease, thus finally realizing the possibility of anti-aging."

Then how the body identify whether free radicals are excess in cell? After using recombinant mouse proteins and recombinant rat proteins, he said, "Nature has wonderful ability in regulation. Lysosome itself has the ability to perceive the radical. MCOLN1 is sensor for ROS reactive oxygen species in lysosomes, and they can regulate autophagy of the cell."

The roe of free radicals in the human body is a double-edged sword: excessive levels can damage cells, while they can also ensure the body's antioxidant capacity at an appropriate level. Therefore, to ensure the balance of free radicals can delay the body's cells aging and enable lysosome to promptly clear harmful substances of the body. Eventually, we found that not every theory is established without any doubt. With the development of science and technology, we will go farther and farther to explore the unknown. Flarebio provides recombinant proteins such as recombinant CDH12 of good quality.

Bacteria have complex enzyme as early as 3.4 billion years ago

A study recently published in the journal Cell Biology Chemistry reveals that 3.4 billion years ago, the ancestors of all bacteria may have enzyme complex, which is only 600 million years later than the origin of life on Earth. This discovery is amazing because scientists used to conclude that the bacteria didn't evolve until much later even 1 billion years after the origin of life. There are also other studies on expressions of recombinant mouse proteins.

Modern enzyme and molecules which they interact with are in correspondence like a lock and key. They usually only "work" for one reaction, but they can get the job done very well. Instead, Michael Harms from the University of Oregon of the United States said that earlier enzymes are "very sloppy" and don't have a relationship of lock and key with the molecules. There are many "pocket" in their structure which can seize a variety of different chemical substances and control many reactions, but none of the tasks can be well executed.

In order to study when modern enzyme appeared, Reinhard Sterner and colleagues from the University of Regensburg, Germany rebuilt a kind of enzyme consists of 4 parts in accordance with the appearance they may seem prior to isolation of modern bacteria and archaea bacteria. This enzyme called tryptophan synthase, aided the generation of a kind of amino acids which are essential to bacteria, archaea, plants and fungi. First, before importing the sequence into the computer program which finds similarities among them, the researchers analyzed the genes that encode this enzyme in modern bacteria and archaea. They then conducted thousands of simulations on the possible appearance of ancient DNA sequence which generated modern genes.

Based on the way that major bacterial populations separated from each other, the program locks one of the most-likely sequences. The team members inserted this "redivious" gene into modern E. coli cells. The gene can copy a large number of genes which were much like the modern version of enzymes. Harms said that this indicates that the time when the bacteria lost their "sloppy" protein was much earlier than people had expected. Meanwhile, DNA residue from billions of years ago does not exist, so this rebuilding experimental study is the only way to study ancient genes. Researchers also can produce some recombinant rat proteins to simulate the process.

However, Mathieu Groussin from the Massachusetts Institute of Technology thought that if researchers can reconstruct some of the other possible protein rather than the most-likely proteins, they would have more confidence in their results. In this case, they will know whether other possible sequences also had a functional protein. More kinds of recombinant proteins such as recombinant CDH12 can be found at Cusabio’s website.